Oral Biologics & Biosimilar Drugs Industry Valued at $15.11 Billion by 2029 With CAGR of 15.1% | Size and Share Insights
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Projected Market Size and Growth Rates for the Oral Biologics & Biosimilar Drugs Market From 2025 To 2029?
In recent times, the market size of oral biologics and biosimilars drugs has expanded significantly. The market is projected to rise from $7.19 billion in 2024 to $8.6 billion in 2025, showing a compound annual growth rate (CAGR) of 19.6%. Factors such as an increasing prevalence of chronic diseases, higher awareness of oral biologics, a surge in patent expirations, and growing demand for biosimilars have contributed to the growth in the historic period.
What Is the Projected Market Size of the Oral Biologics & Biosimilar Drugs Market?
Expectations are set for the oral biologics & biosimilar drugs market to experience accelerated expansion in the coming years. The market valuation is predicted to reach $15.11 billion in 2029, with a compound annual growth rate (CAGR) of 15.1%. This growth during the forecasted period can be credited to elements such as targeted therapy, increased emphasis on preventive medicine, boosts in healthcare expenditure, and an aging population. The forecast period is also likely to witness significant trends such as advances in oral delivery technology, the administration of orally taken biologics, innovations in biosimilars, and a stronger focus on patient-centric care.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3792&type=smp
Who are the Major Competitors in the Oral Biologics & Biosimilar Drugs Market Outlook?
Major companies operating in the oral biologics & biosimilar drugs market include Novartis International AG, Rani Therapeutics Holdings Inc., Eli Lilly and Company, AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals Inc., BiosanaPharma, Entera Bio Ltd., Allergan plc, Emisphere Technologies Inc., Enteris BioPharma Inc., Chiasma Inc., Allena Pharmaceuticals Inc., Gelgen Corporation, 3SBio Inc., Innovent Biologics Inc., Changchun High & New Technology Industries (Group) Inc., Dong Bao Pharmaceutical Co. Ltd., CP Guojian Pharmaceutical Co. Ltd., GlaxoSmithKline PLC, Concord Biotech Limited, Aurobindo Pharma Limited, H. Lundbeck A/S, Sanofi S.A., F. Hoffmann-La Roche Ltd., Allergan Pharmaceuticals International Limited, Hikma Pharmaceuticals PLC, Mylan N.V., Pfizer Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd.
What Is Fueling Growth in the Oral Biologics & Biosimilar Drugs Market?
The increase in ongoing health conditions like arthritis, asthma, and cancer is anticipated to be a key factor propelling the oral biologics and biosimilar market. Prolonged working hours, inadequate physical exercise, along with unhealthy food and beverage consumption, all contribute to the emergence of chronic illnesses, which in turn increases the usage of biologics. Biologics aid in facilitating the immune response to cancer cells, in turn aiding the immune system to eradicate the cancerous cells from the body. For example, according to a United Nations report from May 2023, it’s projected that by 2030, chronic diseases will be responsible for 70% of total global death toll. The global weight of chronic illness is foreseen to approach 60%. Consequently, this surge in chronic diseases’ prevalence is likely to amplify the demand for biologics and biosimilars, thereby boosting the growth of the oral biologics & biosimilar drugs market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=3792&type=smp
Which Oral Biologics & Biosimilar Drugs Market Segments Are Growing the Fastest?
The oral biologics & biosimilar drugs market covered in this report is segmented –
1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors
2) By Disease: Asthma, Crohn’s Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others
3) By Molecule Type: Vaccines, Proteins & Peptides, Monoclonal Antibodies, Other Molecule Types
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Lymphocyte Modulators: Fingolimod, Ocrelizumab, Natalizumab
2) By Interleukin Inhibitors: Ustekinumab, Secukinumab, Guselkumab
3) By Tumor Necrosis Factor-Alpha Inhibitors: Adalimumab, Certolizumab Pegol, Golimumab
Which Industry Trends Are Shaping the Future of the Oral Biologics & Biosimilar Drugs Market?
In the oral biologics and biosimilar market, the formulation of new insulin biosimilars is the most recent trending activity. Major players in the domain are focusing their efforts on crafting an insulin biosimilar, thereby fostering competition among different biosimilar producers. As an illustration, in April 2023, Eli Lilly and Company, a firm based in the US that specializes in creating oral biologics and biosimilar medications, unveiled an insulin glargine biosimilar known as Rezvoglar (insulin glargine-aglr). Insulin glargine products, including this one, are prescribed to enhance glycemic control in adults, and children with type 1 diabetes, as well as adults with type 2 diabetes.
Access The Full Report Here:
Which Countries Are Leading the Oral Biologics & Biosimilar Drugs Market?
The countries covered in the oral biologics & biosimilar drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3792
This Report Delivers Insight On:
1. How big is the oral biologics & biosimilar drugs market, and how is it changing globally?
2. Who are the major companies in the oral biologics & biosimilar drugs market, and how are they performing?
3. What are the key opportunities and risks in the oral biologics & biosimilar drugs market right now?
4. Which products or customer segments are growing the most in the oral biologics & biosimilar drugs market?
5. What factors are helping or slowing down the growth of the oral biologics & biosimilar drugs market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
